ALK and non-small cell lung carcinoma: In NSCLC, G1202R is the most common resistance mutation following treatment with the second generation ALK inhibitors (including ceritinib, brigatinib and alectinib), and lorlatinib is effective in overcoming this resistance mutation [24, 27, 28].